240 related articles for article (PubMed ID: 26709902)
41. Inhibiting poly ADP-ribosylation increases fatty acid oxidation and protects against fatty liver disease.
Gariani K; Ryu D; Menzies KJ; Yi HS; Stein S; Zhang H; Perino A; Lemos V; Katsyuba E; Jha P; Vijgen S; Rubbia-Brandt L; Kim YK; Kim JT; Kim KS; Shong M; Schoonjans K; Auwerx J
J Hepatol; 2017 Jan; 66(1):132-141. PubMed ID: 27663419
[TBL] [Abstract][Full Text] [Related]
42. Regulation of the enzymatic catalysis of poly(ADP-ribose) polymerase by dsDNA, polyamines, Mg2+, Ca2+, histones H1 and H3, and ATP.
Kun E; Kirsten E; Mendeleyev J; Ordahl CP
Biochemistry; 2004 Jan; 43(1):210-6. PubMed ID: 14705947
[TBL] [Abstract][Full Text] [Related]
43. Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors.
Tentori L; Portarena I; Graziani G
Pharmacol Res; 2002 Feb; 45(2):73-85. PubMed ID: 11846617
[TBL] [Abstract][Full Text] [Related]
44. Characterization of sPARP-1. An alternative product of PARP-1 gene with poly(ADP-ribose) polymerase activity independent of DNA strand breaks.
Sallmann FR; Vodenicharov MD; Wang ZQ; Poirier GG
J Biol Chem; 2000 May; 275(20):15504-11. PubMed ID: 10809783
[TBL] [Abstract][Full Text] [Related]
45. Poly-ADP-ribose polymerases (PARPs) as a therapeutic target in the treatment of selected cancers.
Przybycinski J; Nalewajska M; Marchelek-Mysliwiec M; Dziedziejko V; Pawlik A
Expert Opin Ther Targets; 2019 Sep; 23(9):773-785. PubMed ID: 31394942
[No Abstract] [Full Text] [Related]
46. Differentiation-Associated Downregulation of Poly(ADP-Ribose) Polymerase-1 Expression in Myoblasts Serves to Increase Their Resistance to Oxidative Stress.
Oláh G; Szczesny B; Brunyánszki A; López-García IA; Gerö D; Radák Z; Szabo C
PLoS One; 2015; 10(7):e0134227. PubMed ID: 26218895
[TBL] [Abstract][Full Text] [Related]
47. Neuronal trauma model: in search of Thanatos.
Cole K; Perez-Polo JR
Int J Dev Neurosci; 2004 Nov; 22(7):485-96. PubMed ID: 15465278
[TBL] [Abstract][Full Text] [Related]
48. Poly(ADP-Ribose) Polymerase-1 inhibition potentiates cell death and phosphorylation of DNA damage response proteins in oxidative stressed retinal cells.
Martín-Guerrero SM; Casado P; Muñoz-Gámez JA; Carrasco MC; Navascués J; Cuadros MA; López-Giménez JF; Cutillas PR; Martín-Oliva D
Exp Eye Res; 2019 Nov; 188():107790. PubMed ID: 31494107
[TBL] [Abstract][Full Text] [Related]
49. PARP-1 inhibition prevents oxidative and nitrosative stress-induced endothelial cell death via transactivation of the VEGF receptor 2.
Mathews MT; Berk BC
Arterioscler Thromb Vasc Biol; 2008 Apr; 28(4):711-7. PubMed ID: 18239155
[TBL] [Abstract][Full Text] [Related]
50. Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors.
Pacher P; Szabó C
Cardiovasc Drug Rev; 2007; 25(3):235-60. PubMed ID: 17919258
[TBL] [Abstract][Full Text] [Related]
51. Poly (ADP-ribose) polymerase-1 (PARP-1) as immune regulator.
Laudisi F; Sambucci M; Pioli C
Endocr Metab Immune Disord Drug Targets; 2011 Dec; 11(4):326-33. PubMed ID: 21476963
[TBL] [Abstract][Full Text] [Related]
52. Poly(ADP-ribose) polymerase 1 inhibition protects against low shear stress induced inflammation.
Qin WD; Wei SJ; Wang XP; Wang J; Wang WK; Liu F; Gong L; Yan F; Zhang Y; Zhang M
Biochim Biophys Acta; 2013 Jan; 1833(1):59-68. PubMed ID: 23085506
[TBL] [Abstract][Full Text] [Related]
53. Intra-mitochondrial poly(ADP-ribosylation) contributes to NAD+ depletion and cell death induced by oxidative stress.
Du L; Zhang X; Han YY; Burke NA; Kochanek PM; Watkins SC; Graham SH; Carcillo JA; Szabó C; Clark RS
J Biol Chem; 2003 May; 278(20):18426-33. PubMed ID: 12626504
[TBL] [Abstract][Full Text] [Related]
54. Poly(ADP-ribosyl)ation enhancement in brain cell nuclei is associated with diabetic neuropathy.
Kuchmerovska T; Shymanskyy I; Donchenko G; Kuchmerovskyy M; Pakirbaieva L; Klimenko A
J Diabetes Complications; 2004; 18(4):198-204. PubMed ID: 15207836
[TBL] [Abstract][Full Text] [Related]
55. PARP Power: A Structural Perspective on PARP1, PARP2, and PARP3 in DNA Damage Repair and Nucleosome Remodelling.
van Beek L; McClay É; Patel S; Schimpl M; Spagnolo L; Maia de Oliveira T
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34066057
[TBL] [Abstract][Full Text] [Related]
56. Poly(ADP-ribose) Polymerase (PARP) is Critically Involved in Liver Ischemia/Reperfusion-injury.
Haga S; Kanno A; Morita N; Jin S; Matoba K; Ozawa T; Ozaki M
J Surg Res; 2022 Feb; 270():124-138. PubMed ID: 34656890
[TBL] [Abstract][Full Text] [Related]
57. On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1.
Luo X; Kraus WL
Genes Dev; 2012 Mar; 26(5):417-32. PubMed ID: 22391446
[TBL] [Abstract][Full Text] [Related]
58. Modulation of poly(ADP-ribose) polymerase-1 (PARP-1)-mediated oxidative cell injury by ring finger protein 146 (RNF146) in cardiac myocytes.
Gerö D; Szoleczky P; Chatzianastasiou A; Papapetropoulos A; Szabo C
Mol Med; 2014 Jul; 20(1):313-28. PubMed ID: 24842055
[TBL] [Abstract][Full Text] [Related]
59. BGP-15, a nicotinic amidoxime derivate protecting heart from ischemia reperfusion injury through modulation of poly(ADP-ribose) polymerase.
Szabados E; Literati-Nagy P; Farkas B; Sumegi B
Biochem Pharmacol; 2000 Apr; 59(8):937-45. PubMed ID: 10692558
[TBL] [Abstract][Full Text] [Related]
60. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) induces oxidative stress, DNA strand breaks, and poly(ADP-ribose) polymerase-1 activation in human breast carcinoma cell lines.
Lin PH; Lin CH; Huang CC; Chuang MC; Lin P
Toxicol Lett; 2007 Aug; 172(3):146-58. PubMed ID: 17669606
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
